Eric S. Ahn
Eric S. Ahn, MD, MS specializes in oculofacial aesthetic, plastic, and reconstructive surgery who is also a board-certified ophthalmologist. His main areas of interest involves improvement and correction of medical disorders of the eyelid, orbit, skin, face, and neck, in addition to cosmetic surgery and office based procedures.
Eric S. Ahn, MD, MS specializes in oculofacial aesthetic, plastic, and reconstructive surgery who is also a board-certified ophthalmologist.
Medical Education
2004-08
Albany Medical College – Albany, New YorkDoctor of Medicine
2002-03
Georgetown University – Washington, D.C.Master of Science in Biophysics and Physiology
1998-2002
Johns Hopkins University – Baltimore, MarylandBachelor of Arts in Biology
Clinical / Professional Experiences
2015
Samsung Medical CenterSeoul, South Korea
Oculofacial and Reconstructive Surgery Visiting Fellow2015
Hong’s ClinicSuwon, South Korea
Cosmetic and Plastic Surgery Visiting Fellow2015
Casey Eye Institute OHSUPortland, Oregon
Oculoplastic and Reconstructive Surgery Fellowship2012-13
John Hopkins HospitalCleveland, Ohio
Ophthalmology Residency2008-09
Harbor-UCLA Medical CenterCarson, California
Preliminary Medicine Internship
Honors & Awards
- Fellow of the Year
- Ocular Anatomy Award
- Chief Resident & Leadership
- Trustee’s Prize in Pharmacology
- Robert D. Reinecke Research Prize in Ophthalmology
- Alpha Omega Alpha
- Simeus Foundation Award
Memberships
American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS)
Languages
English, Spanish, Korean
Publications and Clinical Trials
SJP 0132 Trial. Sub-Investigator. October 2019, Torrance, CA.
DEG723-P001. Sub-Investiagor. July 2019
ICare study. Sub-Investigator. May 2019, Los Angeles, CA
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle- Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease. Aldeyra Therapeutics. Sub-Investigator. June 2019, Torrance, CA.
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects with Dry Eye Disease. Aldeyra Therapeutics. Sub-Investigator. June 2019, Torrance, CA.
A Phase 3, Multicenter, Randomized, Double–Masked and Placebo–Controlled Study Evaluating the Efficacy and Safety of 0.25% HL036 Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye. HanAll Biopharma, Co., Ltd. Primary Investigator, June 2019, Los Angeles, CA
A Multi-Center, Double-Masked, Randomized,Vehicle- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Bilastine Ophthalmic Solution 0.6% Compared to Vehicle and Zaditen (Ketotifen Ophthalmic Solution 0.025%) for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model. Senju, Primary Investigator, December 2018, Los Angeles, CA
A Double- -Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0. ,001% for the Treatment of Patients with Dry Eye Disease. Senju, Primary Investigator, October 2018, Los Angeles, CA
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis. Aldeyra Therapeutics, Primary Investigator, August 2018, Los Angeles, CA
CYS-003 / 17-110-0009 – A Phase 2b/3, multicenter, randomized, double-masked, vehicle-controlled clinical study to assess the efficacy and safety of topical CyclASol® for the treatment of signs and symptoms of Dry Eye Disease, Novaliq GmbH, Sub-Investigator, October 2017, Los Angeles, CA
NVU-002 – A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease, Novaliq GmbH, Sub-Investigator, December 2017, Los Angeles, CA
Phase 2, Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED). Horizon Pharma, USA, INC. Sub-Investigator, July 2013 – July 2015, Portland, OR
Virongrong Karnsiritanont, MD; Jung-Hyun Ahn, MD; Eric S Ahn, MD; Jisang Han, MD; Kyung-In Woo, MD; Yoon-Duck Kim, MD. Hyaluronic acid gel injection for dysthyroid upper eyelid retraction in Asian patient. Submitted Ophthalmology Journal (AAO).
Ahn ES. Point of view film capture in the operating room. Submitted OPRS 2015.
Ahn ES, Dailey RA. Long term outcomes of conjucntivodacryocystorhinostomy with frosted Jones tubes. Submitted OPRS 2015.
Ahn ES, Hauck MT, Harris JK, Robertson CE, Dailey RA. Bacterial biofilms in Jones tubes. Submitted OPRS.
Mehta M, Ahn ES, Perry JD. Predictability of Optic Foramen Location from a Ray through the Ethmoidal Foramina. 2015ubmitted OPRS 11/2015.
Dailey RA, Marx DP, Ahn ES. Porcine dermal collagen in lower eyelid retraction repair. Ophthal Plast Reconstr Surg. 2015 May-Jun;31(3):233-41
Ahn ES, Patel VR. Horner Syndrome after Radiofrequency Rhizotomy. Completed pending submission. 2013
Ahn ES, Subramanian PS. Treatment modalities of thyroid related orbitopathy. Indian J Ophthalmol. 2014 Oct;62(10):999-1002
Santhiago MR, Ghanem R, Dupps WJ, Ahn ES, Espana E, Wilson SE. Corneal ectasia after LASIK with normal preoperative parameters but thick LASIK flaps. Accepted: Journal of Refractive Surgery, 2012.
Santhiago MR; Ahn ES; Wilson SE. Extremely late-onset breakthrough corneal haze triggered by trauma and treated with phototherapeutic keratectomy. Accepted: Journal of Refractive Surgery, 2011.
Tarabishy AB, Ahn E, Mandell BF, Lowder CY. Central serous retinopathy. Arthritis Care Res. 2011 Apr 26.
Ahn ES, Singh AD, Smith SD. Mantle cell lymphoma with uveal metastasis. Leuk Lymphoma. 2010 Jul;51(7):1354-5.
Simon JW, Ngo Y, Ahn E, Khachikian S. Anisometropic amblyopia and nasolacrimal duct obstruction. J Pediatr Ophthalmol Strabismus. 2009 May-Jun;46(3):182-3.
Ahn ES, Mills DM, Meyer DR, Stasior GO. Sneezing reflex associated with intravenous sedation and periocular anesthetic injection. Am J Ophthalmol. 2008 Jul;146(1):31-5.
Simon JW, Bradfield Y, Smith J, Ahn E, France TD. Recruitment and manpower in pediatric ophthalmology and strabismus. J AAPOS. 2007 Aug;11(4):336-40.
Ahn ES, Singh AD. Isolated Anomaly of the Retinal Pigment Epithelium. Advanced Ocular Care 2010:2.
Ahn ES, Miller NR. Giant Cell Arteritis. Masters Technique in Ophthalmic Surgery. Submitted for publication.
Ahn ES, Tarabishy AB, Schachat AP. Posterior Pole Manifestations of Hematologic Diseasee. Retinal and Choroidal Manifestations of Select Systemic Diseases. Springer 2010.
Ahn ES, Dailey RA. Outcomes and techniques of Voluma injection into the temples. ASOPRS Fall meeting 2016.
Ahn ES, Dailey RA. Lower eyelid position after aesthetic injection of hyaluronic acid filler for midface augmentation. ASOPRS fall meeting 10/2014.
Ahn ES, Ng J. Reconstructive and postoperative management after exenteration. ASOPRS spring meeting 6/2014.
Ahn ES, Mehta MP, Perry JD. Positional Relationship between the ethmoidal foramina and the Optic Canal. ARVO 5/2013.
Ahn ES, Perry JD, Mehta MP, Lewis CD. Repair of moderate and large full thickness eyelid defects with internal cantholysis. Presented at ARVO 5/2012
Ahn ES, Eisengart J, Smith S, Rockwood E. Outcome of Ahmed glaucoma valves in uveitic glaucoma treated without Retistert. Presented at ARVO 5/2011
Ahn ES, Lowder CY, Culver D. The use of chest computerized tomography in the evaluation of non-infectious uveitis, ARVO Poster 5/2010.
No reviews yetAdd Review
